Results 251 to 260 of about 115,586 (310)

Integrating Artificial Intelligence With Droplet‐Based Microfluidics: Advances, Challenges, and Emerging Opportunities

Advanced Intelligent Systems, EarlyView.
Droplet‐based microfluidics enables precise, high‐throughput microscale reactions but continues to face challenges in scalability, reproducibility, and data complexity. This review examines how artificial intelligence enhances droplet generation, detection, sorting, and adaptive control and discusses emerging opportunities for clinical and industrial ...
Junyan Lai, Sukrit Gaira, Rongfeng Wang, Qingtian Zhang, Ming Li, Liao Wu, Diangeng Li, Yi Li, Chengchen Zhang, Jinhong Guo, Shi‐Yang Tang   +10 more
wiley   +1 more source

Molecular engineering of lysosome-based degraders unveils a rapidly expanding therapeutic strategy. [PDF]

Autophagy
Rivault A, Dussart-Gautheret J, Benhida R, Martin AR, Auberger P, Jacquel A, Robert G.   +6 more
europepmc   +1 more source

Bayesian Optimisation for the Experimental Sciences: A Practical Guide to Data‐Efficient Optimisation of Laboratory Workflows

Advanced Intelligent Systems, EarlyView.
This study provides an introduction to Bayesian optimisation targeted for experimentalists. It explains core concepts, surrogate modelling, and acquisition strategies, and addresses common real‐world challenges such as noise, constraints, mixed variables, scalability, and automation.
Chuan He, Martin Singull, T. Jesper Jacobsson   +2 more
wiley   +1 more source

Human DNA polymerase η is regulated by mutually exclusive mono-ubiquitination and mono-NEDDylation. [PDF]

Nucleic Acids Res
Moreno NC, Korchak EJ, Latancia MT, D'Orlando DA, Adegbenro T, Barnes RP, Bezsonova I, Woodgate R, Ashton NW.   +8 more
europepmc   +1 more source

Navigating the Post‐BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

American Journal of Hematology, EarlyView.
ABSTRACT Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies.
Maximilian Al‐Bazaz, Winfried Alsdorf, Lisa Leypoldt, Piet Sonnemann, Christoph Schaefers, Jule Artzenroth, Marie Harzer, Abdulaziz Kamili, Leandra Bartke, Leon Cords, Jan Vorwerk, Theo Leitner, Markus Maulhardt, Kerstin Brinkert, Annamaria Brioli, Tim Richardson, Udo Holtick, Stefan M. Hillmann, Hans Salwender, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Ricardo Kosch   +22 more
wiley   +1 more source

Targeting tumor-infiltrating regulatory T cells: combining CD47 and PD-L1 inhibition via a novel aptamer-siRNA chimera. [PDF]

Mol Biomed
Zeng Y, Chen X, Huang W, Chan CH, Chen Z, Lyu M, Liu Y, Liu M, Lyu A, Mauro C, Yu Y, Cheung KC.   +11 more
europepmc   +1 more source

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics

American Journal of Hematology, EarlyView.
ABSTRACT Pirtobrutinib (PBN), a non‐covalent BTK inhibitor, has been approved by the FDA for relapsed/refractory mantle cell lymphoma (MCL); however, resistance to PBN has been observed. To dissect the molecular dynamics driving PBN resistance, we performed integrative single‐cell multi‐omic profiling (scRNA‐seq, scATAC‐seq, and scDNA‐seq) on ...
Fangfang Yan, Yang Liu, Heng‐Huan Lee, Wei Wang, Joseph McIntosh, Yijing Li, Jovanny Vargas, Yue Fei, Sairah Ahmed, Lukas M. Simon, Michael Wang   +10 more
wiley   +1 more source

A Machine Learning-Guided Approach for Identifying Potential HCAR1 Antagonists in Lactate-Driven Cancers. [PDF]

ACS Omega
Carvalho LV, Seyffert N, Meyer R, Tiwari S, Castro TLP.   +4 more
europepmc   +1 more source

The Engendering of a Chimera: Sources of Independence for Australian Commonwealth State Audit

, 1995
Warwick Funnell
openalex   +1 more source

Post CAR‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse

American Journal of Hematology, EarlyView.
ABSTRACT CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has transformed outcomes for patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL), yet more than 40% relapse within one year. Early identification of patients at risk for progression could inform post CAR‐T surveillance and consolidation strategies.
Snegha Ananth, Neha Agarwal, Bita Sahaf, Allison Jacob, Lik Wee Lee, Heidi Simmons, Ilan Kirsch, Sushma Bharadwaj, Wen‐kai Weng, Melody Smith, Saurabh Dahiya, David Miklos, Matthew J. Frank   +12 more
wiley   +1 more source